GLPG
Price:
$27.98
Market Cap:
$1.66B
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Industry
Biotechnology
IPO Date
2012-02-27
Stock Exchange
NASDAQ
Ticker
GLPG
According to Galapagos N.V.’s latest financial reports and current stock price. The company's current Current Ratio is 32.82. This represents a change of 42.60% compared to the average of 23.02 of the last 4 quarters.
The mean historical Current Ratio of Galapagos N.V. over the last ten years is 4.03. The current 32.82 Current Ratio has changed 81.37% with respect to the historical average. Over the past ten years (40 quarters), GLPG's Current Ratio was at its highest in in the June 2026 quarter at 32.82. The Current Ratio was at its lowest in in the September 2021 quarter at 0.
Average
4.03
Median
0
Minimum
0
Maximum
20.15
Discovering the peaks and valleys of Galapagos N.V. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual Current Ratio = 20.15
Minimum Annual Increase = 0%
Minimum Annual Current Ratio = 0
| Year | Current Ratio | Change |
|---|---|---|
| 2025 | 20.15 | Infinity% |
| 2024 | 0 | 0% |
| 2023 | 0 | 0% |
| 2022 | 0 | 0% |
The current Current Ratio of Galapagos N.V. (GLPG) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
6.72
5-year avg
4.03
10-year avg
4.03
Galapagos N.V.’s Current Ratio is greater than argenx SE (5.12), greater than Assembly Biosciences, Inc. (13.99), greater than CytomX Therapeutics, Inc. (9.36), greater than Kyntra Bio, Inc. (2.69), greater than NextCure, Inc. (3.47), greater than Ultragenyx Pharmaceutical Inc. (1.73), greater than Spero Therapeutics, Inc. (6.12),
| Company | Current Ratio | Market cap |
|---|---|---|
| 5.12 | $61.92B | |
| 13.99 | $502.17M | |
| 9.36 | $613.92M | |
| 2.69 | $28.74M | |
| 3.47 | $20.48M | |
| 1.73 | $1.43B | |
| 6.12 | $64.85M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Galapagos N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Galapagos N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Galapagos N.V.'s Current Ratio?
How is the Current Ratio calculated for Galapagos N.V. (GLPG)?
What is the highest Current Ratio for Galapagos N.V. (GLPG)?
What is the 3-year average Current Ratio for Galapagos N.V. (GLPG)?
What is the 5-year average Current Ratio for Galapagos N.V. (GLPG)?
How does the current Current Ratio for Galapagos N.V. (GLPG) compare to its historical average?